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Editorial Comment
Improved Early Infarct-Related
Vessel Patency After
Thromholytic Therapy*
BERTRAM PITT, MD, FACC
Arrrr Arbor, Michigan
The major goal of reperfusion strategies in patients with
acute myocardial infarction is to achieve patency of the
infarct-related artery . Improvement in ventricular function
and survival are related to initial and continued potency of
this artery . The greater initial patency of the infarct-related
artery after intravenous recombinant tissue-type plasmino-
gen activator (r(-PA) compared with that achieved with
intravenous streptokinase in the Thrombolysis in Myocar-
dial Infarction (TIM[) trial (I) led to the selection of rt-PA as
the thrombolytic agent of choice in the United States
.
With current intravenous thrombolytic strategies, the
highest potency rate achieved is 75% . Early use of intrave-
nous heparin and the use ofcombined thrombolytic regimens
have failed to break through this ceiling (2-4), which may be
a result of several factors. These include complexity of the
atherosclerotic plaque with intramural plaque hemorrhage
(5), ongoing platelet deposition into the thrombus with
resistance to thrombolysis iii1 as well as inadequate throm-
bolytic effectiveness or dose of the chosen thrombolytic
agent .
The failure of current intravenous thmmbulylie strategies
to achieve a higher patency rate of the infarct-related artery
has led to several adjunctive and alternative strategies for
reperfusion, Rescue angioplasty for patients with failed
intravenous thrombolysis has been evaluated in several trials
(7) . However, initial results have been disappointing because
of a relatively high rate of complications including death
.
The failure of rescue angioplasty may be related to platelet
activation, particularly aftcrrt-PA and mechanical trauma to
the residual thrombus, resulting in reocclusion
. Several
investigators (8) have achieved a high patency rate by using
direct coronary angioplasty without intravenous thrum-
hntytic therapy ("direct" angioplasty)
. A patency rate of
>90% has been achieved with a relatively low complication
rate with this strategy . Although feasible, this strategy has
only limited applicability because of the limited availability
of angioplasty facilities and laboratories willing to operate on
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a 24-t, basis with immediate access for the patient with acute
infarction . Even if further rand - mized trials show an advan-
tage for this strategy, it is unlikely (hat, given the logistic
didlCUlties associated with its use, we will achieve a major
improvement in ventricular function and sarival in large
numbers of patients with acute r ..^socardial infarction .
'fhepresentsstudy . The recent rudy by Neuhaus nt al . 19)
demonstrating an improved early tvdency rat, of >90th with
front-loaded rt-PA, infusing 10u mg of ti-PA over 90 min
without an apparent increase in bleeding risk, is therefore of
great interest and has important therapeutic potential .
Should this strategy result in an improved cony and sus-
tained potency rate there would he a lesser impetus to pursue
the strategy of rescue angioplasty and a lesser justification
for early coronary arteriography . The strategy of direct
coronary angioplasty without thrombolytic therapy might
also lose some of its appeal it early administration of
front-loaded rt-PA achieves a high rate of initial and sus-
tained potency of the infarct-related artery . The study by
Neuhaus dial. (10) in this issue of the Journal is therefore of
importance in giving us some initial perspective on the
potential of the front-loaded re-PA regimen to achieve and
maintain patency of the infarct-related artery in comparison
with intravenous APSAC . Neuhaus et al . (l0) show that
front-loaded it-PA achieved a 90-min palency rate of 84 .4%
versus 70
.3% for intravenous APSAC . However, because of
a higher reocclusion rate with front-loaded n-PA, at l4 to 21
days the two regimens had a similar patency rate . The
greater initial palency rate with the front-loaded rt-PA regi-
men was associated with a significantly lower in-hospital
mortality rate. The finding in this study that initial infarct-
vessel patency is associated with improved survival lends
encouragement to the development of combined throm-
bulytic strategies (I l) and further use of adjunctive strategies
with antithrombin or antihbrin platelet agents such as hirudi n
or antagonists to the glycoprotein Ilbillla platelet receptor
(12-14). These agents have the potential to achieve even
greater initial patency as suggested by initial animal studies
(13) . If the high rate of reocclusion associated with rt-PA, as
documented in this study (10),
could be reduced by adjunc-
tive autipla€elet therapy, one might expect even greater
benefit for survival since reocclusion is associated with a
loss of functional recovery and an increase in mortality (15) .
Implications. One should, however, be cautious in adopt-
ing the strategy of front-loaded rt-PA before seeing the
results of far larger prospective randomized trials demon-
strating its safety and ei'hcacy over a longer period of title .
The greater early patency of the infarct-related vessel with
standard n-PA dosing regimens than with intravenous strep-
tokinase (I) did not result in improved survival when these
agents were compared in the GISSI-2 (16) and ISIS-3 (17)
trials . Although there has been criticism of both of these
trials relating to their delayed subcutaneous heparin regi-
mens, one would have expected that intravenous n-PA in
these trials should have achieved greater initial patency of
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the infarct-related artery, al least in comparison with intra-
venous streptokina a
. The tack o : early intravenous heparin
in these trials would be expected to have a greater influence
on reoeelusion than on initial patency . Because Neuhaus et
al . (10) suggest that early rather i
.ran late palcttc5 i,
importance in improving survival, one would have expected
improved survival in the r:-PA arm of the GISSI-2 (161 and
ISIS-3 trials (17), at least in comparison with intravenous
strepokinase
. Whether trial design or factors other ihnn
infarct-vessel patency account for the failure of rt-PA to
demonstrate improved survival despite its early patency
advantage remains to he determined .
.A far larger noinber of
patients, in the range of 10
.0(0 per treatment arm. will also
be needed to be studied before we can assess the effect
of
front-loaded rt-PA or any other regimen on the incidence of
major bleeding, which is approximately IV, with standard
thrombolytic regimens (17) . Although there was a lower
incidence of bleeding mooned in the trial
by Neuhaus el a!.
(10), with front-loaded en-PA Clam with APSAC- as the
authors point out, this difference may be due to the use of
early intravenous heparin, which may not be necessary with
intravenous
APSAC given the lower incidence of reocclu-
Sion associated with its use .
Conclusions. Thus, whi .a it appears that we cat achieve
improved early patency by front-loaded r0--PA and could
likely achieve even better initial and sustained patency by
the addition
of adjunctive antiplatelet therapy, we still have
much to learn concerning the dose
of thrombolytic therapy
as well as the addition and timing of heparin and other
adjunctive therapies. Neuhaus et al . (10) have given us hope
for improved survival by improved early infarct vessel
patency. To achieve the full potential of the thrombolytic era
we will need to further explore this and other dosing regi-
mens of thrombolytic agents with new adjunctive therapies.
Clearly we have much to learn . The GISSI 2 (16) and ISIS-3
(17) trials mark the end of one phase of our exploration for
the optimal reperfusion strategy. The next phase is just
beginning
. Although it is premature to predict which throm-
bolvtic agent will he the agent of choice, it is not too early to
predict that we will achieve greater early and sustained
patency with improved functional recovery and survival by
further careful study of strategies now under develnptnent
and in or soon to be in clinical trial
.
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